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Abstract.  Microbia l secondary metabol ites have 
emerged as alternative novel drugs for the treatment of 
human cancers. Violacein, a purple pigment produced 
by Chromobacterium violaceum, was investigated in the 
present study for its anti-tumor properties in tumor cell 
lines. Clinically applicable concentrations of violacein were 
demonstrated to inhibit the proliferative capacity of tumor 
cell lines according to a crystal violet proliferation assay. The 
underlying mechanism was the promotion of apoptotic cell 
death, as indicated by poly(ADP ribose) polymerase cleavage 
and p44/42 mitogen-activated protein kinase signaling deter-
mined by western blot analysis. Collectively, this provided 
mechanistic evidence that violacein elicits extracellular-signal 
regulated kinase-induced apoptosis via the intrinsic pathway. 
The anti-malignant properties of violacein in the present study 
were further demonstrated by its inhibitory effects on brain 
tumor cell migration, specifically glioblastomas, one of the 
most invasive and therapeutically resistant neoplasms in the 
clinic. Additionally, solid tumors examined in the present 
study displayed differential cellular responses and sensitivities 
to violacein as observed by morphologically induced cellular 
changes that contributed to its anti-migratory properties. In 
conclusion, violacein is a novel natural product with the poten-
tial to kill several types of human tumor cell lines, as well as 
prevent disease recurrence by antagonizing cellular processes 
that contribute to metastatic invasion.
Introduction
The utility of bacteria as agents for the treatment of cancer was 
described over a century ago and continues to be investigated 
for their therapeutic value as delivery agents for anti-cancer 
drugs and vectors for gene therapy (1-3). Additionally, 
contemporary strategies have also studied the use of bacterial 
products, including proteins, enzymes, immunotoxins and 
secondary metabolites for their anti-tumor properties (1-3). An 
advantage of these alternatives is the lack of systemic infec-
tion associated with the use of live, attenuated and engineered 
bacterial strains for cancer therapy (1-3). 
In the present study, the secondary metabolite violacein, a 
pigment produced by the bacteria Chromobacterium viola-
ceum, was investigated as an anti-tumor agent, which has been 
shown to have medicinal applications as an antibiotic and 
anti-trypanosoma agent (4,5). The use of bacterial metabo-
lites such as violacein as anti-cancer agents is supported by 
pre-clinical studies with other microbial products, including 
farnesyltransferase inhibitors (6-14), prodigines (15-17) and 
epothilones (18-22), which have displayed positive therapeutic 
efficacy in several types of cancer and were subsequently 
examined in phase I and II clinical trials. More specifically, 
violacein has been shown to have anti-cancer properties in 
leukemia (23,24) and colon cancer cells (25-27), as well as in 
Ehrlich ascites tumors by Bromberg et al (28) using an in vivo 
mouse model. In contrast to these studies, the present study 
used violacein extracted from a Chromobacterium violaceum 
strain native to a copper basin in Tennessee, which was demon-
strated here to have anti-proliferative effects on cell lines 
derived from solid tumors, as well as displayed an inhibitory 
effect on cancer cell migration, extending the anti-tumorigenic 
properties of this bacterial-produced metabolite.
Materials and methods
Cell conditions and reagents. U87 (glioblastoma), A549 
(lung) and MCF7 (breast) cancer cells were purchased from 
the American Type Culture Collection (Manassas, VA, USA). 
All cell lines were maintained in Dulbecco's Modified Eagle's 
Medium (DMEM; Invitrogen Life Technologies, Carlsbad, 
CA, USA) containing 10% fetal bovine serum (Invitrogen 
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Life Technologies), 2 mM L-glutamine (Invitrogen Life 
Technologies), 100 nM MEM non-essential amino acids 
(Invitrogen Life Technologies) and penicillin-streptomycin 
(Invitrogen Life Technologies) at 37˚C and 5% CO2. 
Isolation and characterization of violacein. Chromobacterium 
violaceum was collected from environmental soil and 
water samples at the Tennessee Copper Mining Company 
site (Ducktown, TN, USA), also termed the Copper Basin. 
Chromobacterium violaceum were inoculated in Luria-
Bertani broth (LB) media, streaked and grown on agar plates 
for 48 h at 30˚C, until colonies formed. The colonies were 
subsequently selected and grown as cultures in LB broth 
media for 24-48 h at 30˚C. The cultures were used to extract 
and purify violacein, as described previously (29). Cultures 
were centrifuged at 14,629 x g in 100% ethanol for 15 min 
at 4˚C and the supernatant was collected, and violacein was 
separated and extracted using chloroform. The violacein was 
allowed to dry for 24 h and dissolved in 50% ethanol (Fisher 
Scientific, Fair Lawn, NJ, USA). Violacein was subsequently 
purified with reverse phase column chromatography and char-
acterized by liquid chromatography-mass spectrometry and 
ultraviolet-visible spectroscopy.
Crystal violet cell proliferation assay. Cells were plated in 
24-well plates, treated with 250 nM, 500 nM and 1 µM violacein 
and allowed to incubate for 48 h ([vehicle controls were treated 
with dimethyl sulfoxide (DMSO; Amresco, LLC, Solon, OH, 
USA)] for dose-response experiments. For time-course experi-
ments, cells were treated with 1 µM violacein and allowed 
to incubate for 1, 3 and 5 days. Subsequently, tissue culture 
medium was removed, the cell monolayer was fixed with 
100% methanol for 5 min and stained with 0.5% crystal violet 
in 25% methanol for 10 min. Cells were then washed three 
times for 5 min each with distilled water to remove excess 
dye and allowed to dry overnight at room temperature. The 
incorporated dye was then solubilized in 0.1 M sodium citrate 
(Sigma-Aldrich; St. Louis, MO, USA) in 50% ethanol. Next, 
100 µl treated and control samples were transferred to 96-well 
plates and optical densities read at 540 nm using an X-mark 
microplate absorbance spectrophotometer (Bio-Rad, Hercules, 
CA, USA). 
Cell motility. Motility assays were conducted according to 
the manufacturer's instructions (Cell Biolabs Inc., San Diego, 
CA, USA). A cell suspension containing 0.5-1.0x106 cells/ml 
was prepared in serum-free media with vehicle (DMSO) or 
1 µM violacein, while 500 µl of media containing 10% fetal 
bovine serum was added to the lower chamber of the migra-
tion plate. 300 µl of the cell suspension containing vehicle or 
1 µM violacein was then added to the inside of each insert 
and allowed to incubate for 24 hours at 37˚C and 5% CO2. 
Subsequently, non-migratory cells were removed from the 
plate inserts (per manufacturer's instructions), migratory cells 
were counterstained, solubilized, and optical density densities 
read at 595 nm using a X-mark microplate absorbance spectro-
photometer (Bio-Rad Laboratories).
Western blot analysis. Cells were plated and treated with 
1 µM violacein for 24 h or vehicle (DMSO), rinsed with 
phosphate-buffered saline (Bio-Rad Laboratories, Hercules, 
CA, USA), and lysed with CelLytic M Cell lysis reagent 
(Sigma-Aldrich, St Louis, MO, USA). Protein concentrations 
were subsequently determined using the Bradford reagent 
(cat. no. B6916; Sigma-Aldrich). Proteins were separated by 
8% SDS-PAGE (Bio-Rad Laboratories) and then transferred 
to nitrocellulose membranes. For immunoblotting, nitrocel-
lulose membranes were incubated with phosphorylated (p)
Akt (rabbit monoclonal; cat. no. 4606), cleaved poly(ADP 
ribose) polymerase (PARP; rabbit polyclonal; cat. no. 9544), 
p44/42 (rabbit monoclonal; cat. no. 4370), and pS6-ribosomal 
protein (rabbit monoclonal; cat. no. 4858) and β-actin (rabbit 
polyclonal; cat. no. 4967), purchased from Cell Signaling 
Technology (Danvers, MA, USA) and all diluted 1:25, recog-
nizing target proteins overnight at 4˚C. The membranes were 
then incubated with a horseradish peroxidase-conjugated 
goat anti-rabbit secondary antibody (1:100; cat. no. 7074; Cell 
Signaling Technology) for 3 h at room temperature, analyzed 
using an enhanced chemiluminescence detection system 
with SuperSignal West Pico Chemilluminescent Substrate 
(cat. no. 34080; Thermo Fisher Scientific, Waltham, MA, USA) 
and visualized by autoradiography using a BioSpectrum UVP 
Imaging System  (BioSpectrum, Upland, CA, USA). Actin was 
used as loading control.
Statistical analysis. Values are expressed as the mean ± stan-
dard error. Significance was determined using Student's t-test. 
P<0.05 was considered to indicate a statistically significant 
difference between values.
Results
Violacein antagonizes brain, lung and breast cancer cell 
proliferation. Lung and breast cancer are two of the most 
Figure 1. Dose response and sensitivity of solid tumor cell lines to violacein. 
Violacein caused a significant decrease in cell viability of U87 brain tumor 
cells and A549 lung cancer cells in contrast to MCF7 breast cancer cells. 
Shown is a dose-response experiment performed in duplicate representative 
of three independent experiments that showed similar results. White bars, 
vehicle dimethyl sulfoxide; black bars, 1 µM violacein; dark grey bars, 
500 nM violacein; light grey bars, 250 nM violacein. Error bars represent the 
standard error. *P<0.05 compared to vehicle-treated control cells.
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common types of cancer found in men and women, and have 
high incidence of metastasis to the brain (30). The present 
study therefore evaluated the effects of violacein on three 
solid tumor cell lines, U87 (brain), A549 (lung) and MCF7 
(breast). Dose-response experiments were performed at the 
outset to assess the effects of several violacein concentrations 
(250 nM, 500 nM and 1 µM) on cell viability. Cell viability 
dose-response assays revealed a 56-, 34- and 12%-decrease 
in U87 cells treated with 1 µM, 500 nM and 250 nM viola-
cein as compared to the viability of vehicle treated control 
cells, respectively, while A549 cells displayed a 54, 11 and 
8%-decrease in viability when treated with identical concen-
trations compared to that of vehicle-treated control cells 
(Fig. 1). By contrast, MCF7 cell viability did not decrease in 
response to violacein exposure using this assay.
The anti-proliferative effects of violacein have been 
attributed to its ability to elicit a cytotoxic response in 
several human cancers (23,27,31-33), as well as induce 
differentiation, a cytostatic response observed in leukemia 
cells by Melo et al (26). To gain better insight into the effect 
of violacein on cell proliferation in brain, lung and breast 
cancer cells, time course experiments were preformed in the 
present study. Examination of U87, A549 and MCF7 cells 
treated with 1 µM violacein revealed a reduction in cell 
proliferation of all three cell lines over a five-day period, 
with a statistically significant difference (P<0.05) in cell 
viability observed on day five between vehicle-treated 
control cells and violacein-treated cells (Fig. 2). Time course 
analysis also revealed that U87 and A549 cells were more 
sensitive to violacein treatment as compared to MCF7 cells, 
which displayed a two-fold increase in cell viability five 
days post-violacein treatment as compared to cell viability 
on day 0 (Fig. 2). These data were consistent with dose 
response experiments that also showed that U87 and A549 
cells were more sensitive to violacein exposure than MCF7 
cells. The findings of the present study parallel a study by 
Menezes et al (34), which showed that crude extracts of 
violacein were differentially toxic to several human tumor 
cell lines, including the multi-drug-resistant ovarian tumor 
cell line NCI/ADR-RES.
Violacein promotes PARP and p44/42 mitogen-activated 
protein kinase (MAPK) signaling. The mechanistic effects 
of violacein on cellular responses have proven to be varied 
and tumor type-specific. Of note, violacein has been shown 
to upregulate p53, p27 and p21, which are negative regula-
Figure 2. Anti-proliferative effects of violacein on cancer cells. The mitotic 
capacity of U87 brain tumor and A549 lung cancer cells was inhibited in 
response to treatment with 1 µM violacein, while violacein decreased the 
proliferative rate of MCF7 breast cancer cells. Values are representative of 
three independent experiments performed in duplicate that showed similar 
results. Diamonds, vehicle dimethyl sulfoxide; squares, 1 µM violacein. Error 
bars represent the mean±standard error. *P<0.05 compared to vehicle-treated 




Figure 3. Regulation of survival and apoptotic signaling proteins by violacein. 
(A) Violacein had no effect on pAkt protein levels in solid tumor cell lines 
examined, (B) but substantially induced expression of the pro-apoptotic pro-
tein cleaved PARP in brain and lung cancer cells. (C) Additionally, violacein 
upregulated p44/42 MAPK protein levels in brain tumor cells. Immunoblots 
displayed are representative of at least three independent experiments that 
showed comparable results.
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tors of cell cycle progression (24), and to induce reactive 
oxygen species-mediated apoptotic cell death in colon cancer 
cells (23). Additionally, Ferreira et al (27) demonstrated that 
violacein promoted leukemia cell death via tumor necrosis 
factor signaling. To address the mechanisms of the anti-prolif-
erative response of violacein on solid tumor cells described 
above, several intracellular signaling proteins were analyzed 
for changes in their expression when exposed to various 
concentrations of this agent. The survival and pro-apoptotic 
proteins, Akt and PARP, were examined in U87, A549 and 
MCF7 cells exposed to violacein. A substantial induction of 
cleaved PARP was observed in U87 brain tumor cells treated 
with 500 nM violacein, as well as in A549 lung cancer cells 
treated with 1 µM violacein (Fig. 3). By contrast, no changes in 
the activity of Akt expression were observed in cells exposed 
to violacein (Fig. 3). Additional protein expression analysis 
revealed that 500 nM violacein upregulated p-44/42 MAPK 
in U87 cells. This result was similar to that observed in 
leukemia cells, which displayed increased p38 MAPK expres-
sion in response to violacein (27). Furthermore, violacein 
did not affect the expression levels of pS6 ribosomal protein 
(Fig. 3), providing additional evidence along with the lack of 
Figure 4. Effects of violacein on tumor cell migration. Violacein (A) considerably reduced brain tumor cell migration and (B) had a diminutive effect on lung 
cancer cell migration. Shown are boyden chamber assays performed in duplicate that are representative of three independent experiments that exhibited similar 
results (magnification, 40x). Aa and Ba, cells treated with vehicle dimethylsulfoxide; Ab and Bb, cells treated with 1 µM violacein. OD, optical density.
Figure 5. Violacein induces morphological changes that affect tumor cell motility. (A-C) Cells treated with vehicle dimethylsulfoxide. (D) U87 brain tumor 
cells displayed a transient round cellular phenotype in response to treatment with 1 µM violacein, that was absent in (E) lung and (F) breast cancer cells. 
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expressional changes of pAkt protein described above, that 
this secondary metabolite does not mechanistically influence 
the translational control signaling network.
Impairment of tumor cell migration in response to violacein. 
The effect of violacein on cellular biological processes that 
underlie metastatic invasion has not been sufficiently inves-
tigated to date, to the best of our knowledge. In the present 
study, the ability of violacein to inhibit cellular processes that 
contribute to the metastatic invasion of cancers, which leads 
to therapeutic resistance and recurrence of this disease, were 
therefore evaluated. Boyden chamber assays revealed that 
1 µM violacein decreased the migration of U87 cells by 40% 
as compared to that of vehicle-treated control cells, while a 
diminutive decrease was observed in A549 violacein-treated 
cells (Fig. 4). The anti-migratory response, particularly of 
U87 cells, may be attributed in part to violacein-induced 
morphological changes (Fig. 5). U87 cells exposed to 500 nM 
violacein appeared to detach from the cell substratum and 
exhibited a round cellular phenotype three hours post-expo-
sure, which was not observed in A549 and MCF7 cells after 
treatment with violacein (Fig. 5). However, cell adhesion assays 
performed revealed that violacein did not affect the adhesive 
properties of U87 brain tumor cells (data not shown). It should 
also be mentioned that U87 cells re-attached and displayed 
normal cell morphology when examined 24 h after violacein 
exposure, indicating the violacein-induced morphological 
changes were not a consequence of cells undergoing cell death. 
In conclusion, these results suggested that violacein-induced 
morphological changes had an impact on the migratory ability 
of U87 brain tumor cells. 
Discussion
The efficacy of therapeutic agents used to treat human cancers 
is dependent upon their ability to antagonize molecular 
signaling events that contribute to the survival of tumor cells 
and induce regulatory mechanisms that promote their death. 
The present study investigated a novel secondary metabolite, 
violacein, produced by a chromobacterium, for its utility as an 
agent that can promote tumor cell death in solid tumor-derived 
cell lines. It was shown that violacein considerably reduced 
the proliferative capacity of lung and brain cancer cells, and 
to a much lesser extent that of breast cancer cells, providing 
an indication that cancers are differentially sensitive to this 
agent. This difference in sensitivity and responsiveness was 
also manifested mechanistically as demonstrated in the 
ability of violacein to promote apoptotic cell death by upregu-
lating cleaved PARP, a downstream target of the effector 
pro-apoptotic molecule caspase 3, in brain and lung cancer 
cells. Additionally, p44/42, a known apoptosis-promoting 
regulator and caspase 3 activator, was increased in brain 
tumor cells treated with violacein. These results established 
that violacein-induced apoptosis observed in the present study 
likely occurs via the intrinsic pathway, particularly in brain 
tumor cells, which is consistent with studies on leukemia, 
fibrosarcoma and colon cancer cells that have demonstrated 
the apoptosis-promoting properties of violacein by intrinsic as 
well as extrinsic pathways (23,27,35). It should also be noted 
that violacein has been described to elicit other types of cell 
death, as shown in resistant leukemia cells that underwent cell 
death as a consequence of endoplasmic reticulum stress and 
breakdown of the golgi apparatus, underscoring the tumor cell 
killing capacity of violacein via different cell death mecha-
nisms (25). 
Although several studies, including the present study, have 
provided evidence of violacein's ability to promote tumor 
cell death, its role as an agent that can prevent the meta-
static invasion of cancer cells has received little attention. 
The present study showed that violacein inhibited brain 
tumor cell migration, likely as a consequence of disrupting 
sub-cellular domain structures of the actin filamentous 
network, including the lamellipodia and filopodia, that led 
to a round cellular phenotype that compromised the motility 
of these cells. To the best of our knowledge, the present 
study was the first to show that violacein inhibits cancer cell 
migration, extending the anti-malignant properties of this 
agent. Additionally, the anti-migratory effects of violacein 
on cancer cells demonstrated in the present study are further 
supported by a recent study by Platt et al (36), which showed 
that violacein inhibited the secretion of the pro-cell migra-
tory inflammatory chemokine CXCL12 in breast cancer cells. 
These results suggested that violacein may have therapeutic 
applications that prevent brain tumor cells from invading 
normal brain tissue, as well as inhibit brain metastases from 
breast cancer, the most common source of metastatic brain 
tumors in women (30). 
In conclusion, violacein has potential as a therapeutic 
agent to treat cancer due to its versatility to cause cell death in 
several types of cancer and prohibit metastatic invasion. The 
potential of violacein to be used as a cancer drug is further 
supported by the recent U.S. Federal Drug Administration's 
approval of romidepsin, a histone deactylase inhibitor 
produced by Chromobacterium violaceum, for the treatment 
of T-cell lymphoma (37), as well as a renewed interest in 
cancer therapies utilizing bacteria and bacterial products (1-3) 
to selectively target cancer cells.
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